Navrogen Inc.
Therapeutic biologics targeting immunosuppressive pathways in humoral immunity for cancer treatment
- Sector
- Biotech
- Headquarters
- CHEYNEY, PA
- Founded
- 2017
- Latest Form D
- $542K, Jun 2024
- Total capital
- $8.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $8.8M
- 3 Form D · last Jun 2024
- 28 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 9 pending · first 2026
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$542K
- Private capital raisedForm D · SEC · 2nd filing$7M
- Private capital raisedForm D · SEC · 1st filing$1.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Nicholas C. NicolaidesResearcherExecutive Officer, DirectorLinked by 1 patent
- Allan C. BedwickDirectorNamed in SEC Form D filings
- Leon O Moulder, JrDirectorNamed in SEC Form D filings
- Leon O. Moulder, Jr.DirectorNamed in SEC Form D filings
- Luigi C. GrassoExecutive Officer, DirectorNamed in SEC Form D filings
- Steven G KyriakosExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 10- PendingFc-Engineered Monoclonal Antibodies Refractory to Tumor Immunosuppressive ICAM-1/CD54USPTOApplication 19104036
- GrantedComposition and Use of Humoral Immune Suppressor Antagonists for the Treatment of Humoral Immune Suppressed DiseasesUSPTOUS 12,516,096
- PendingComposition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of CancerUSPTOApplication 18026518
Show all 10 patent records
- Fc-Engineered Monoclonal Antibodies Refractory to Tumor Immunosuppressive ICAM-1/CD54Apr 9, 2026 · Application 19104036Pending
- Composition and Use of Humoral Immune Suppressor Antagonists for the Treatment of Humoral Immune Suppressed DiseasesJan 6, 2026 · US 12,516,096Granted
- Composition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of CancerDec 14, 2023 · Application 18026518Pending
- Composition and Use of Engineered Monoclonal Antibodies Refractory to Tumor Immuno-Suppressive FactorsJun 29, 2023 · Application 17789746Pending
- Composition And Use Of Alternatively Formatted Anti-mesothelin Antibodies For The Treatment Of CancerApplication PCTUS2021052286Pending
- Composition And Use Of Engineered Monoclonal Antibodies Refractory To Tumor Immuno-suppressive FactorsApplication PCTUS2020067345Pending
- Composition And Use Of Humoral Immune Suppressor Antagonists For The Treatment Of Humoral Immune Suppressed DiseasesApplication PCTUS2020045245Pending
- Fc-engineered Monoclonal Antibodies Refractory To Tumor Immunosuppressive ICAM-1/CD54Application PCTUS2023072162Pending
- Humoral Immune Activators for the Treatment of Humoral Immunosuppressed Pathologies, Cancer and Infectious Disease and Humoral Immune Suppressors for the Treatment of Inflammatory DiseasesApplication 18867520Pending
- Humoral Immune Activators For The Treatment Of Humoral Immunosuppressed Pathologies, Cancer And Infectious Disease And Humoral Immune Suppressors For The Treatment Of Inflammatory DiseasesApplication PCTUS2023068472Pending
Related companies, and why
- Trail Software, Inc.Similar federal contract value in Biotech · null in contracts
- Growth Curve Bio, LLCSimilar federal contract value in Biotech · null in contracts
- PeproMene Bio, Inc.Similar federal contract value in Biotech · null in contracts
- ELIXIRGEN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Fountain Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Appello Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .